Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02861573
Title Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | child
Covered Countries USA | TUR | SWE | POL | NZL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS


No variant requirements are available.